Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334876 · ClinicalTrials.gov registry record · NA
Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 571
- Enrollment target
NCT04334876: Completed NA study, sponsored by Indiana University.
NCT04334876 is a NA study that has completed, run by Indiana University. The registered enrollment target is 571 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04334876, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 571 participants
- Enrollment target
Study Summary
The purpose of this study is to validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers. Additionally, we would like to evaluate the incidence of seroconversion in this high-risk population and to identify possible candidates for convalescent plasma donation for therapy/prophylaxis.
Primary Outcome
To determine the number of high risk health care workers with a positive SARS CoV2 IgG on a rapid, at home, self-administered, point-of-care (POC) test. Positive POC tests were then assessed for confirmation using a serum antibody test.
Interventions
- DIAGNOSTIC_TEST SARS-CoV-2 IgG Antibody Testing Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2021-01-01 |
| Phase | NA |
What the finished NCT04334876 record still lists
NCT04334876 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 IgG Antibody Testing Kit is the first listed.
NCT04334876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04334876 about?
NCT04334876 is a clinical study titled "Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers". The purpose of this study is to validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers. Additionally, we would like to evaluate the incidence of seroconversion in this high-risk population and to identify possible candidates for convale...
What is the current status of trial NCT04334876?
This trial is currently completed. It is a NA study. The enrollment target is 571 participants. The study started on 2020-04-01. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT04334876?
The interventions under investigation include: SARS-CoV-2 IgG Antibody Testing Kit (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04334876?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04334876's enrollment target sits among peer trials
571 180th of 2000 higher than 1,821 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI